Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15385 | 0.91 | SMN1; SMN2 (0.63) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| Benzoyl Peroxide SCHEMBL1326365 | 0.90 | RAB9A (0.62) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL31347990 | 0.90 | RAB9A (0.62) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL2152936 | 0.90 | RAB9A (0.62) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL4358091 | 0.88 | RAB9A (0.52) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL28924800 | 0.83 | SMN1; SMN2 (0.59) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL22619 | 0.82 | CES2 (0.59) | RAB9ANPC1HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL22115811 | 0.82 | CES2 (0.59) | RAB9ANPC1HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL6945787 | 0.82 | RAB9A (0.58) | RAB9ANPC1HPGDL3MBTL1CASP3 | |
| SCHEMBL1396691 | 0.82 | RAB9A (0.54) | RAB9ANPC1HPGDL3MBTL1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280989-B1 | CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS | SCYNEXIS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9090671-B2 | Macrocyclic peptides | SCYNEXIS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CYPRALIS LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312300-A1 | NOVEL MACROCYCLIC PEPTIDES | CHP1, SARS1, HAVCR2 | RAB9A 2802/4885NPC1 999/4885HPGD 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.